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Editorial Comment 
Atria1 Natriuretic Factor: 
Its Role in Hypertension* 
EDWARD D. FROHLICH, MD, FACC 
Neus Orlems, Louisiana 
The story of the atrial natriuretic factor is a fascinating one. 
Over an extremely short time. a putative hormone was 
suggested. its biochemical characteristics were identified. 
the amino acid sequence was determined, the peptide was 
cloned and the pure hormone was made available through 
recombinant technology. Thus, thanks to modern day high 
technology, a new hormone, one originating in the heart. 
was identified and commercially synthesized. Yet industry 
became frustrated because the commercial potential of atria1 
natriuretic factor made available through “high tech” devel- 
opments outpaced the physiologic knowledge about its role 
in health and disease. The latter requires the luxury of time 
to permit acquisition of biologic (e.g., physiologic, biochem- 
ical) information, scientific interchange at meetings and in 
publications and, of course, confirmation of the data. It is 
inevitable that this experience will recur in the future. 
Pathophysiology of atrial natriuretic factor. In this issue 
of the Journal (1) we are presented with new physiologic 
information concerning the role of atrial natriuretic factor in 
health and disease. Before commenting on this article, I will 
examine briefly the teleology of the pathophysiology of atrial 
natriuretic factor. Consider the circumstances of a volume- 
overloaded circulation. Here we find a situation of an 
increased venous return to the heart and an expanded 
cardiopulmonarv volume. Ideally, if the heart could “sense” 
this overload in-its low pressure chamber and then initiate a 
response to induce natriuresis and diuresis, this would 
provide the negative feedback that we expect from finely 
tuned circulatory homeostasis. Indeed, we now know that 
atrial stretch associated with volume overload serves to 
release atrial natriuretic factor from the atrium: this, in 
turn, stimulates the renal excretion of sodium (and water), 
which restores a normal cardiopulmonary volume and circu- 
lation (2). 
However, the foregoing events are only partially true and 
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certain data are, at present, conflicting. As a result, the 
teleology is not totally supported. On the one hand, early 
studies demonstrated that, in vitro, atria1 natriuretic factor 
reduced vascular smooth muscle tone in vessel strip prepa- 
rations and produced a potent natriuresis and diuresis with 
minimal kaliuresis in vivo (3). On the other hand, in the total 
body situation. atrial natriuretic factor has been shown to 
reduce arterial and venous pressures associated with a 
reduced cardiac output and an increased total peripheral 
resistance (4). These findings, of course, suggest a question- 
able role for atrial natriuretic factor in cardiac failure and a 
less than ideal action for a new antihypertensive agent. 
Commercial interests were soon diverted to providing the 
hormone for investigative and radioimmunoassay purposes 
rather than for therapeutic goals. However, more recently, 
long-term infusion of atrial natriuretic factor was shown to 
decrease total peripheral resistance (5) and to increase 
cardiac output in patients with cardiac failure (6). These 
responses have been difficult to utilize clinically because of 
the short half-life of the native peptide, although current 
studies reported in abstracl form (7-9) using endopeptidase 
inhibitors that interfere with the degradative metabolism of 
atrial natriuretic factor support a potential role for this 
peptide in the treatment of hypertension. 
Present study. Data are now becoming available on the 
role of atrial natriuretic factor in health and disease (1). In 
their study, tianau et al. (I) were concerned with the relation 
of atrial natriuretic factor to systemic hemodynamics and 
cardiac structure in patients with systemic arterial hyperten- 
sion. Well established essential hypertension is character- 
ized by an elevated arterial pressure secondary to an in- 
creased total peripheral resistance that is associated with a 
contracted intravascular (plasma) volume and with adaptive 
structural changes characterized by left ventricular hyper- 
trophy and vessel wall thickening (IO). Even before these 
changes are found in patients with established essential 
hypertension, the elevated arterial pressure may be related 
to an increased cardiac pulmonary volume. This increased 
volume elevates cardiac output in association with an “in- 
appropriately normal” total peripheral resistance that would 
actually be reduced in normal subjects with that degree of 
elevation in cardiac output (I I). The incremental increase in 
cardiopulmonary volume (and cardiac output) results from 
peripheral venoconstriction that redistributes the (normal) 
circulating intravascular volume centrally. In this regard, 
alterations in atrial natriuretic factor levels have been shown 
with related physiologic interventions and in disease. Thus, 
with cardiopulmonary volume expansion or peripheral veno- 
constriction (e.g., water immersion), or both, atrial natri- 
uretic factor levels increase. In certain diseases associated 
with expanded cardiopulmonary volume, such as congestive 
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heart failure or mitral stenosis, and after paroxysmal atrial Furthermore, patients with milder hypertension may also 
tachycardia, atria1 natriuretic factor levels also are in- have a higher total peripheral resistance, which would 
creased. Each of these conditions is associated with atrial suggest some degree not only of precapillary constriction but 
distension and a ready stimulus for atria1 natriuretic factor also of postcapillary constriction that increases the vascular 
release (12). resistance. These changes serve to reduce plasma volume 
Ganau and associates (I) evaluated the various physio- (16) and are also probable in the patients of Ganau et al. (1) 
logic and clinical determinants of atrial natriuretic factor in because of their higher hematocrit levels. The changes arc 
normal subjects and patients with essential hypertension. consistent with the plasma renin activity levels the investi- 
They demonstrated that immunoreactive plasma atrial natri- gators found: they should be reduced, particularly in nor- 
uretic factor levels were directly related to age. systolic motensive subjects. 
pressure and echocardiographically mensurated left atrial Conclusions. Thus, the findings of this study (1) demon- 
and ventricular chamber sizes in normal subjects, but that strate several important concepts. First. immunoreactive 
only age and ventricular size were independent predictors of atrial natriuretic factor is elevated in patients with mild to 
the hormonal levels. In patients with essential hypertension. moderately severe essential hypertension. This elevation 
the atrial natriuretic factor levels were directly related to may relate to an increased central distribution of circulating 
age, systolic pressure, atria1 size. total peripheral resistance volume that reflects peripheral arteriolar and venular con- 
and ventricular systolic performance, although age, atrial striction. Supporting this thesis are the findings of higher 
size and vascular resistance were independent predictors. cardiac output, total peripheral resistance and hematocrit in 
Ganau et al. therefore suggest that. in normal subjects, these patients that were associated with the increased levels 
impaired ventricular relaxation with age may contribute to of atria1 natriuretic factor. The findings of a direct relation 
atrial natriuretic factor secretion. They state that correlation with age and systolic pressure are also consistent with stiffer 
with left ventricular size may relate to fluctuations in plasma cardiac chambers and peripheral vessels in patients with 
volume; the latter was not measured. and plasma and hypertension and in normal subjects with aging. With more 
cardiopulmonary volumes do not expand with aging. Ganau severe degrees of hypertension, arterial pressure increases 
et al. suggest that in the patients with uncomplicated hyper- in proportion to the increase in total peripheral resistance; in 
tension, left atria1 enlargement contributes to atrial natri- association with these changes. the left ventricle undergoes 
uretic factor release, and they show that there was no hypertrophy. Because cardiac output was maintained in 
relation with left ventricular hypertrophy or systolic func- these patients, venous return was normal. However, be- 
tion. Furthermore, it is of particular interest that the atrial cause of the less compliant cardiac chamber, atrial natri- 
natriuretic factor levels and plasma renin activity were uretic factor remained stimulated. 
inversely related in patients with essential hypertension, and In the final analysis, we are now learning more of the role 
Ganau et al. suggest an inhibitory effect of atrial natriuretic of atrial natriuretic factor in health and disease and can relate 
factor hormone on renin release from the kidney. changes in its circulating levels and release mechanisms to 
Role of intravascular (plasma) volume expansion. In this pathophysiologic alterations. As we learn of its relation to 
respect these speculations relating changes with intravascu- hemodynamic and cardiac functions, we shall know more of 
lar (plasma) volume with atrial natriuretic factor levels its therapeutic potential. Until then, new data such as these 
would appear to merit further consideration. It is unfortu- from Ganau et al. (I) are welcome. 
nate that plasma volume was not determined because this 
variable is a major determinant of both atrial natriuretic 
factor secretion and plasma renin activity. Thus. with vol- References 
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